{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunosuppression+Reduction&page=3", "query": { "intervention": "Immunosuppression Reduction", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 83, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunosuppression+Reduction&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immunosuppression+Reduction&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T10:26:06.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05077254", "title": "COVID Protection After Transplant-Immunosuppression Reduction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplant Recipients", "Liver Transplant Recipients" ], "interventions": [ { "name": "Pfizer-BioNTech COVID-19 Vaccine 2023-2024", "type": "BIOLOGICAL" }, { "name": "Moderna COVID-19 Vaccine 2023-2024", "type": "BIOLOGICAL" }, { "name": "SOC IS Regimen", "type": "DRUG" }, { "name": "SOC IS Reduction", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2021-12-06", "completion_date": "2025-02-21", "has_results": true, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 15, "location_summary": "San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05077254" }, { "nct_id": "NCT02659891", "title": "IVIg to Treat BK Viremia in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Transplantation", "BK Virus", "Isoantibodies" ], "interventions": [ { "name": "IVIg", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2016-05", "completion_date": "2021-03-31", "has_results": false, "last_update_posted_date": "2021-09-05", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02659891" }, { "nct_id": "NCT01649609", "title": "Using mTOR Inhibitors in the Prevention of BK Nephropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BK Viremia", "BK Nephropathy" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate acid", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2012-03", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-28", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01649609" }, { "nct_id": "NCT03663933", "title": "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoproliferative Disorders", "Autoimmune Lymphoproliferative", "Primary T-cell Immunodeficiency Disorders", "Immune System Diseases", "Common Variable Immunodeficiency" ], "interventions": [ { "name": "e-ATG", "type": "DRUG" }, { "name": "Immunosuppression Only Conditioning", "type": "PROCEDURE" }, { "name": "Reduced Intensity Conditioning", "type": "PROCEDURE" }, { "name": "GVHD Prophylaxis", "type": "DRUG" }, { "name": "Allogeneic HSC", "type": "PROCEDURE" }, { "name": "Bisulfan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MMF", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Pentostatin", "type": "DRUG" }, { "name": "PFTs", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspirate & Biopsy", "type": "PROCEDURE" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "2D ECHO", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 71, "start_date": "2018-09-04", "completion_date": "2030-04-03", "has_results": true, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03663933" }, { "nct_id": "NCT04670926", "title": "Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Kidney Transplant Rejection", "Immunosuppression" ], "interventions": [ { "name": "TruGraf", "type": "DIAGNOSTIC_TEST" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Transplant Genomics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2021-06-03", "completion_date": "2023-09-30", "has_results": false, "last_update_posted_date": "2021-08-27", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04670926" }, { "nct_id": "NCT04933799", "title": "IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Pneumonia" ], "interventions": [ { "name": "PF-06650833", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Giovanni Franchin, M.D, Ph.D", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2021-01-06", "completion_date": "2022-05-06", "has_results": false, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933799" }, { "nct_id": "NCT01598987", "title": "Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Function", "Liver Transplant" ], "interventions": [ { "name": "Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Month to 17 Years" }, "enrollment_count": 56, "start_date": "2012-10", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2017-05-16", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 9, "location_summary": "Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598987" }, { "nct_id": "NCT07862439", "title": "Biomarker-guided Reduction of Immunosuppression in Liver Transplant Recipients (BRITRE)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Diseases" ], "interventions": [ { "name": "miRNA Biomarker-Guided Immunosuppression Minimization", "type": "OTHER" }, { "name": "Conventional Biochemical Monitoring-Guided Immunosuppression Minimization", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2027-01", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07862439" }, { "nct_id": "NCT04304820", "title": "Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia" ], "interventions": [ { "name": "Eltrombopag", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Horse-Anti-thymocyte-Globulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "3 Years to 99 Years" }, "enrollment_count": 80, "start_date": "2020-05-07", "completion_date": "2033-12-18", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04304820" }, { "nct_id": "NCT00031655", "title": "Reduced Intensity Donor Stem Cell Transplant in Treating Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Lymphoblastic Leukemia in Remission", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "donor lymphocytes", "type": "BIOLOGICAL" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 30, "start_date": "2001-09", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2012-12-07", "last_synced_at": "2026-10-19T10:26:06.721Z", "location_count": 3, "location_summary": "Portland, Oregon • Seattle, Washington", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031655" } ] }